Impact of $^{18}$F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer

A Systematic Review and Meta-analysis

Sangwon Han, MD,* and Joon Young Choi, MD, PhD†

Objectives: We performed a systematic review and meta-analysis to evaluate the impact of $^{18}$F-FDG PET, PET/CT, and PET/MRI on staging and management during the initial staging of breast cancer.

Methods: We searched the PubMed, Embase, Cochrane Library, and KoreaMed databases until March 2020 to identify studies that reported the proportion of breast cancer patients whose clinical stage or management were changed after PET scans. The proportion of changes was pooled using a random-effects model. Subgroup and metaregression analyses were performed to explore heterogeneity.

Results: We included 29 studies (4276 patients). The pooled proportions of changes in stage and management were 25% (95% confidence interval [CI], 21%–30%) and 18% (95% CI, 14%–23%), respectively. When stage changes were stratified according to initial stage, the pooled proportions were 11% (95% CI, 3%–22%) in stage I, 20% (95% CI, 16%–24%) in stage II, and 34% (95% CI, 27%–42%) in stage III. The relative proportions of intermodality and intention-to-treat changes were 74% and 70%, respectively. Using metaregression analyses, the mean age and the proportion of intermodality and intention-to-treat changes were 74% and 70%, respectively.

Conclusions: Currently available literature suggests that the use of $^{18}$F-FDG PET, PET/CT, and PET/MRI leads to significant modification of staging and treatment in newly diagnosed breast cancer patients. Therefore, there may be a role for routine clinical use of PET imaging for the initial staging of breast cancer.

Key Words: breast neoplasms, $^{18}$F-FDG, positron emission tomography, neoplasm staging, meta-analysis

Breast cancer is the most common malignancy and the second leading cause of cancer-related deaths in women.¹ It is critical to accurately assess the extent of regional and distant disease in newly diagnosed breast cancer to optimize therapeutic decisions and clinical outcomes. Current oncologic practice guidelines do not systematically recommend $^{18}$F-FDG PET/CT for the initial staging of breast cancer; the use of $^{18}$F-FDG PET or PET/CT is not indicated in patients whose clinical stage is between I and operable III unless there is suspicion for metastatic disease, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology guidelines.²,³ The use of $^{18}$F-FDG PET/CT is recommended in the setting of advanced breast cancer⁴,⁵; however, the European Society for Medical Oncology guideline states that PET/CT can be used instead of, but not in addition to, CT and bone scan.⁶ The National Institute for Health and Clinical Excellence guideline recommends PET/CT only for the diagnosis of metastatic disease in patients with advanced breast cancer whose imaging is suspicious but not diagnostic of metastasis.⁷ The Centers for Medicare and Medicaid Services in United States reimburses $^{18}$F-FDG PET in breast cancer staging for distant metastasis except for axillary lymph nodes,⁸ although the National Oncologic PET Registry, which supports the decision for PET coverage, has a limited database of breast cancer. In summary, the routine use of $^{18}$F-FDG PET/CT in early breast cancer is not recommended, and the use of $^{18}$F-FDG PET/CT in addition to other staging imaging modalities is not generally recommended even in advanced breast cancer unless standard imaging results are equivocal by currently available guidelines.

Nevertheless, a number of meta-analyses indicate that $^{18}$F-FDG PET/CT has high diagnostic accuracy for the evaluation of regional and distant metastases,⁹–¹¹ as well as prognostic implications in newly diagnosed breast cancer patients.¹¹ Likewise, a recently published systematic review reported that the currently available literature suggests superior diagnostic efficacy of $^{18}$F-FDG PET/CT compared with other staging modalities for the detection of regional and distant metastasis in newly diagnosed breast cancer.¹² In recent decades, a growing body of evidence has shown that additional findings on $^{18}$F-FDG PET/CT produce a significant change in the initial staging and therapeutic management of breast cancer.¹³–²⁰ This literature suggests that the yield from PET/CT is considerable not only for high-risk patients (those with locally advanced or inflammatory breast cancer) but also for intermediate-risk patients who have clinical stage II breast cancer or higher.¹¹ Some of the researches even indicate that $^{18}$F-FDG PET/CT may have a substantial influence on early breast cancer.¹⁶,²²,²₄,³⁰ The advent of PET/MRI, with its excellent diagnostic performance, may also impact clinical practice in breast cancer treatment,⁴² and a comprehensive review of the role of $^{18}$F-FDG PET scans including PET/MRI is required. Hence, we performed a systematic review and meta-analysis of the available literature on the impact of $^{18}$F-FDG PET, PET/CT, and PET/MRI on clinical stage and management at initial staging in breast cancer patients.

PATIENTS AND METHODS

This meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.³¹ The
protocol was registered to the International Prospective Register of Systematic Reviews network (registration number CRD42020168949).

**Literature Search and Extraction**

PubMed, Embase, Cochrane Library, and KoreaMed database were searched from inception to March 21, 2020. Search queries included the related terms “breast cancer,” “initial staging,” “18F-FDG PET,” and “impact,” which are described in the supplementary materials (Supplemental Digital Content 1, http://links.lww.com/CMN/A302). There was no language restriction for the electronic search. The references of the extracted articles were examined to look for additional relevant articles.

The inclusion criteria were created based upon the Patient, Intervention, Comparator, Outcome, and Study design criteria. We included studies that had (1) female “patients” with newly diagnosed breast cancer; (2) 18F-FDG PET, PET/CT, or PET/MRI at initial staging as the “intervention”; (3) no “comparator”; (4) changes in staging or therapeutic plan after 18F-FDG PET, PET/CT, or PET/MRI when compared with the initial stage or plan based on clinical, pathological, and conventional imaging results as the “outcome”; and (5) “study design” as original articles. The exclusion criteria included the following: (1) small sample size (<10 patients); (2) other publication types including conference abstracts, review articles, editorials, and letters; (3) articles irrelevant to the research question; (4) insufficient information provided in the study to calculate the proportion of changes in staging and management; and (5) overlapping study populations. We included studies in which PET scan was performed in the preoperative or early postoperative period but before any systemic treatment or radiation therapy (RT). When study populations may have overlapped, we selected the publication with the largest population for the meta-analysis.

**Data Extraction and Quality Assessment**

The outcomes, studies, and patient characteristics of each included study were extracted using a standardized form. The methodologic quality of the included studies was appraised using the Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS) tool. Study selection, data extraction, and quality assessment were performed by 2 independent reviewers (S.H. and J.Y.C.). Disagreement, if present, was resolved via discussion.

**Data Synthesis and Analysis**

The primary outcome of this study was the impact of 18F-FDG PET, PET/CT, or PET/MRI on staging and management, which was specifically measured using the proportion of patients whose disease stage or therapeutic plan changed due to imaging findings on 18F-FDG PET, PET/CT, or PET/MRI. The change in stage included both up- and down-staging as reported on individual studies after 18F-FDG PET compared with initial clinical stage based on conventional workup. The secondary outcomes were as follows: (1) exploration of heterogeneities via subgroup and metaregression analyses; (2) proportion of changes in stage after 18F-FDG PET based on initial stage; and (3) proportion of intermodality and intention-to-treat changes in management. The metaregression analyses were performed using clinical variables, which allowed the number of the included studies to be more than...
| Author | Year | Design | Patients, n | Inclusion Criteria | FDG-Dose, MBq | Uptake Time, min | Scanner | Confirmation of Lesions on PET |
|--------|------|--------|-------------|--------------------|---------------|-----------------|---------|-----------------------------|
| Bernsdorf et al12 | 2012 | P | 103 | Operable tumor ≥2 cm with no suspicion of bilateral cancer, M0 or N0 | 400 | 60 | PET/CT | Histology; if not feasible, then imaging follow-up |
| Cermik et al13 | 2008 | P | 240 | Not specified | ≥2 cm | 45-110 | PET/CT | Histology or imaging follow-up |
| Chandra et al14 | 2020 | R | 158 | Stage I-III, T1-2 N0-1 | 5.2/kg | 60 | PET/CT | Histology or clinical follow-up |
| Cochet et al15 | 2014 | R | 142 | Tumor ≥T2 | 5/kg | 60 | PET/CT | Histology, imaging, and clinical follow-up |
| Evangelista et al16 | 2017 | P | 275 | ≥N1 or large tumor or HER2+ or TNBC | 3/kg | 60 | Histology or clinical follow-up |
| Fuster et al17 | 2008 | P | 60 | Noninflammatory, tumor >3 cm | 740 | 60 | PET/CT | Histology (imaging follow-up for multiple metastases) |
| Gajjala et al18 | 2018 | P | 61 | Stage III | 370 | 60 | PET/CT | Histology, if not feasible, then imaging follow-up |
| Garami et al19 | 2012 | NR | 115 | Tumor <4 cm; no sign of M1 or N3 | 4.4–5.5/kg | 60 | PET/CT | Histology or imaging |
| Garg et al20 | 2016 | P | 79 | LABC (stage III) | NR | NR | PET/CT | Typical lesions: considered positive; others: histology or imaging follow-up |
| Groheux et al21 | 2011 | P | 254 | Stage II-III | 5/kg | 60 | PET/CT | Histology or imaging |
| Gunalp et al22 | 2012 | R | 267 | Grade II-III; preoperative (n = 141); postoperative (n = 126) | 5/kg | 60 | PET/CT | Histology or clinical follow-up (MRI for bone foci) |
| Jeong et al23 | 2014 | R | 178 | No clinical sign of N+ | 5.2/kg | 60 | PET/CT | Histology, if not feasible, then imaging follow-up |
| Klaeser et al24 | 2007 | R | 114 | Intermediate or high risk; preoperative (n = 73); postoperative (n = 41) | 370 | 45–60 | PET/CT | Histology or imaging |
| Koolen et al25 | 2014 | P | 62 | Neoadjuvant RT group: age ≥60 and tumor ≤3 cm; NAC group: T1 and ≥N1 | 180–240 | 60 ± 10 | PET/CT | Histology or imaging |
| Krammer et al26 | 2015 | P | 101 | ≥T2 or ≥N1 or large tumor or HER2- or TNBC | 199–350 | 60 | PET/CT | Histology or imaging |
| Landheer et al27 | 2005 | P | 175 | ≥N1 at level 2 axillary node or with a high mitotic activity index | 200–220 | 60 | PET/CT | Histology or imaging follow-up |
| Manohar et al28 | 2013 | P | 43 | LABC | 370–444 | 60 | PET/CT | Histology or imaging follow-up |
| Ng et al29 | 2015 | P | 154 | Stage III | 5/kg | 60 | PET/CT | NR |
| Ng et al30 | 2016 | R | 19 | Stage I-III | 5/kg | 60 | PET/CT | NR |
| Pereková et al31 | 2018 | R | 17 | Not specified | 370–555 | <90 | PET/CT | Histology or imaging |
| Becker et al32 | 2010 | R | 106 | Stage IB-III | 4.5/kg | 60 | PET/CT | Histology or imaging |
| Segert et al33 | 2013 | R | 77 | Not specified | 370–555 | 60 | PET/CT | Histology or imaging |
| Taneja et al34 | 2014 | R | 36 | Not specified | 400 ± 56 | 48 ± 12 | PET/CT | Histology or imaging |
| Ulaner et al35 | 2016 | R | 232 | Stage I-IIIC, TN | 444–555 | 60 | PET/CT | Histology, if not feasible, then imaging follow-up |
| Ulaner et al36 | 2017 | R | 483 | Stage I-IIIC; ER+/HER2− (n = 238); HER2+ (n = 245) | 444–555 | 60 | PET/CT | Histology, if not feasible, then imaging follow-up |
| Walker et al37 | 2012 | R | 62 | Inflammatory breast cancer | 555–740 | 60 ± 90 | PET/CT | Histology, if not feasible, then imaging follow-up |
| Yasarbas et al38 | 2018 | R | 234 | Not specified | 222–641 | 60 | PET/CT | Typical lesions: considered positive; others: histology, if not feasible, imaging follow-up |

LABC, locally advanced breast cancer; NAC, neoadjuvant chemotherapy; NR, not reported; P, prospective cohort study; R, retrospective cohort study; TNBC, triple-negative breast cancer.
| Author                          | Mean Age (Range) | Initial Stage, % | Histology‡ (Ductal/Lobular/Other, %) | Grade (I/II/III, %) | Receptor Phenotypes (ER+/PR+/HER2+, %) | Molecular Subtypes (Luminal A/B/HER2/TN) |
|--------------------------------|------------------|------------------|--------------------------------------|---------------------|----------------------------------------|------------------------------------------|
| Bernsdorf et al¹²              | 55 (24–81)       | NR               | 80/14/6                              | 11/52/36            | 72/55/21                               | NR/NR/NR/13                              |
| Cermik et al¹³                 | 51 † (24–80)     | NR               | NR                                   | NR                  | NR                                     | NR                                       |
| Chandra et al¹⁴                | 56               | I: 14; IIA/B: 60/26 | NR                                   | I–II/III: 44/56     | NR                                     | 19/48/14/20                              |
| Cochet et al¹⁵                 | 51 (25–85)       | II/A: 15/30; IIIA/B/C: 8/13/11; IV: 12 | 90/8/2                              | I–II/III: 57/39     | 63/56/34                               | 36/31/11/22                              |
| Evangelista et al¹⁶ (preoperative) | 53               | I/II/III: 5/46/48 | 87/12/1                              | 1/20/69             | NR                                     | 11/50/9/28                               |
| Evangelista et al¹⁶ (postoperative) | 54               | I/II/III: 21/35/44 | 83/9/6                               | 3/22/75             | NR                                     | 12/57/14/16                              |
| Fuster et al¹⁷                 | 57               | IIIB: 65; IIIA/B/C: 11/6/5; IV: 13 | 87/13/0                              | NR                  | NR                                     | NR                                       |
| Gajjala et al¹⁸                | 51 (27–78)       | IIA/B/C: 23/68/9  | 98/0/2                               | NR                  | 13/49/12/26                            | NR                                       |
| Garami et al¹⁹                 | NR               | I/I: 55/43       | 80/10/10                             | NR                  | 77/NR/14                               | NR                                       |
| Ghar et al²⁰                  | 50 † (18–80)     | III: 100         | 98/0/2                               | NR                  | NR                                     | NR                                       |
| Groheux et al²¹                | NR               | II/A: 17/22; IIIA/B/C: 25/29/7 | 86/8/6                              | 4/46/47             | ER+/HER2−: 51; HER2+: 20               | TN: 27                                   |
| Gunalp et al²² (preoperative)  | 47 (28–78)       | I: 13; IIA/B: 36/35; IIIA/B: 9/1; IV: 6 | NR                                  | II–III: 100         | NR                                     | NR                                       |
| Gunalp et al²² (postoperative) | 48 (25–75)       | NR               | NR                                   | II–III: 100         | NR                                     | NR                                       |
| Jeong et al²³                 | 55 (33–82)       | T1/2/3: 61/36/3; N0: 100; M0: 100 | 82/6/12                              | NR                  | NR                                     | NR                                       |
| Klaeser et al²⁴               | 59 (32–83)       | I: 6; IIA/B: 36; IIIA/B/C: 15/20/13; IV: 10 | 61/5/34                              | NR                  | NR                                     | NR                                       |
| Koolen et al²⁵                | 59 (26–75)       | T1: 100; N0/1/2/3: 56/40/0/3; M0: 100 | 94/2/4                              | 34/47/15            | ER+/HER2−: 77; HER2+: 11               | TN: 11                                   |
| Krammer et al²⁶               | 54               | IIA/B: 51/23; IIIA/B/C: 9/5/1; IV: 11 | 77/14/9                              | 5/46/43             | 64/54/54                               | NR                                       |
| Landheer et al²⁷              | 58 (29–80)       | All N(+)         | NR                                   | NR                  | NR                                     | NR                                       |
| Manohar et al²⁸                | 49 (28–80)       | IIIA/B/C: 35/56/2 | NR                                   | NR                  | NR                                     | NR                                       |
| Ng et al²⁹                    | 49 (26–70)       | IIIA/B: 13/53; IIIA/B/C: 28/5/2 | NR                                   | 5/36/55             | 64/56/34                               | NR                                       |
| Nursal et al³⁰               | 52               | I: 25; II: 75    | 73/7/20                              | NR                  | 74/59/42                               | NR                                       |
| Piperkova et al³¹             | 55 (30–80)       | NR               | 63/30/7                              | NR                  | NR                                     | NR                                       |
| Reddy Akepati et al³²          | 54               | IIA/B: 18/26; IIIA/B/C: 13/25/2; IV: 11 | 91/1/8                              | 4/85/11             | NR                                     | NR                                       |
| Rieger et al³³                | 57 (25–84)       | IA: 17; IIA/B: 36/18; IIIA/B/C: 5/4/2; IV: 15 | 79/16/5                              | 10/57/35            | NR                                     | NR                                       |
| Segaaert et al³⁴              | 56 (23–84)       | IIIB: 16; III: 84 | 90/10/0                              | NR                  | 76/64/NR                               | NR                                       |
| Sen et al³⁵                   | 52 † (26–87)     | II/I/III/IV: 25/49/23/3 | 80/4/16                              | NR                  | NR                                     | NR                                       |
| Taneja et al³⁶                | 50 (34–75)       | NR               | 100/0/0                              | 6/64/14             | NR                                     | NR                                       |
| Ulaner et al³⁷                | 51 † (25–93)     | I: 10; IIA/B: 35/38; IIIA/C: 10/1 | 94/1/5                              | 0/3/94             | 0/0/0                                  | TN: 100                                 |
| Ulaner et al³⁸ (ER+/HER2−)     | 55 † (27–89)     | I: 6; IIA/B: 30/40; IIIA/B/C: 10/11/3 | 79/14/7                              | 2/16/77            | 100/85/0                               | NR                                       |
| Ulaner et al³⁸ (HER2+)         | 50 † (26–78)     | I: 9; IIA/B: 29/38; IIIA/B/C: 13/9/2 | 92/3/5                              | 0/7/89             | 67/53/100                              | NR                                       |
| Walker et al³⁹                | 49 † (26–78)     | T4d: 100; N0/1/2/3: 3/29/66; M0/1: 77/23 | NR                                   | 0/37/52            | 48/39/45                               | NR                                       |
| Yarbas et al³⁰                | 53 (23–87)       | IA–B: 1; IIA/B: 18/28; IIIA/B/C: 35/7/10 | 72/6/22                              | NR                  | NR                                     | NR                                       |

*Patient characteristics were only available for the whole study population in whom PET/CT was performed for restaging as well as for staging.
†Median.
‡Other histologic types include mixed, papillary, mucinous, apocrine, neuroendocrine, undifferentiated, atypical medullary, and adenosquamous carcinoma.
NR, not reported; PR, progesterone receptor; TN, triple-negative breast cancer.
or equal to 10.45 Intermodality change was defined as an alteration in the type of management (eg, RT, surgery, systemic treatment, or multimodal treatment including a combination of RT, surgery, and systemic treatment).46 Intention-to-treat change was defined as modification of treatment intent (eg, a change from curative to palliative approach).

The proportions were transformed using the Freeman-Tukey double arcsine method47 and were then meta-analytically pooled using the DerSimonian-Liard method for calculating weights with the “meta” and “metafor” packages in R software (version 3.6.3; R Foundation for Statistical Computing, Vienna, Austria). Clopper-Pearson confidence intervals were used for individual studies. Higgins I² statistics were used to assess heterogeneity.48 Funnel plots with Egger test were drawn to appraise the presence of publication bias.49

RESULTS

Study Characteristics

An electronic search retrieved 2054 articles (Fig. 1); of these, 81 articles were potentially eligible. After full-text review, we excluded 52 articles for the following reasons: no inclusion of changes in staging or management (n = 14), reports of either nodal or distant metastasis but without calculation of a patient-based proportion (n = 13), no initial staging (n = 10), overlapping study population (n = 9), dedicated breast PET scan (n = 3), comparison of high-resolution versus standard resolution PET/CT (n = 1), and not about PET, PET/CT, or PET/MRI (n = 2). Thus, 29 studies with 4276 patients were included in the meta-analysis.12–40 Of note, there were 3 studies that included patients in whom PET/CT was performed in the preoperative and postoperative setting and patients with differential receptor phenotypes (estrogen receptor [ER]+/human epidermal growth factor receptor 2 [HER2]− and HER2+) and separately evaluated each population16,22,38; these patients were considered as separate cohorts in the meta-analysis. Detailed study and patient characteristics are described in Tables 1 and 2. Table 3 summarizes the type of conventional staging procedures used in the included studies.

Quality Assessment

Study quality was considered moderate to good, with 25 of 29 studies satisfying at least 5 of the 8 RoBANS domains (Fig. 2). All studies were rated as having a low risk of bias in comparability of participants, incomplete outcome data, and selective outcome

| Author | MG | Breast US | Breast MRI | CXR | BS | US Other Sites | CT | MRI Other Sites | Pathology |
|--------|----|-----------|------------|-----|----|----------------|----|----------------|-----------|
| Bernsdorf et al12 | + | + | - | + | - | - | - | - |
| Cermik et al13 | - | - | - | - | - | - | - | + (Surgery) |
| Chandra et al14 | + | - | - | - | - | - | - | + (Surgery/FNA) |
| Cochet et al15 | + | + | ± | ± | - | + | - | + (C/AP); +(brain); +(Brain) |
| Evangelista et al16 | + | + | ± | ± | - | + | - | ± |
| Fuster et al17 | - | - | + | ± | + | + | - | +(Liver); +(AP) |
| Gajjala et al18 | + | + | + | + | +(C/A) | +(AP) |
| Garami et al19 | + | + | + | + | +(AP) |
| Garg et al20 | - | - | - | - | + | + | +(A) |
| Groheux et al21 | + | + | + | + | +(Liver) |
| Gunalp et al22 | + | + | + | + | +(Liver) |
| Jeong et al23 | + | + | + | - | - | +(AP) |
| Klaeser et al24 | - | - | ± | ± | - | - | +(C/AP) |
| Koolen et al25 | ± | + | ± | ± | - | - | +(A) |
| Kramer et al26 | + | + | + | + | +(A) |
| Landheer et al27 | - | - | - | - | + | +(C/A) |
| Manohar et al28 | - | - | - | - | + | +(A) |
| Ng et al29 | + | + | - | - | - | +(C/AP) |
| Narsal et al30 | + | + | + | - | - | +(C/AP) |
| Piperkova et al31 | NR | NR | NR | NR | NR | NR | NR | NR |
| Reddy Akepati et al32 | - | - | - | + | + | +(A) |
| Riegger et al33 | + | + | + | + | +(Liver) |
| Segelart et al34 | - | - | - | - | - | - | +(C/A) |
| Sen et al35 | - | - | - | - | ± | - | +(A) |
| Taneri et al36 | - | - | - | - | - | - | +(A) |
| Ulaner et al37 | + | + | + | + | +(A) |
| Ulaner et al38 | - | - | - | - | - | - | +(C/A) |
| Walker et al39 | + | + | + | + | - | - | +(A) |
| Yarbas et al40 | ± | ± | ± | ± | ± | ± | ± |

± indicates those performed in the selected patients.

A, abdominal; AP, abdominopelvic; BS, bone scan; C, chest; CNB, core-needle biopsy; CXR, chest x-ray; FNA, fine-needle aspiration; MG, mammography; NR, not reported; US, ultrasound.
FIGURE 2. Quality assessment using the RoBANS tool.

FIGURE 3. A forest plot shows the pooled proportion of changes in stage compared between $^{18}$F-FDG PET, PET/CT, and PET/MRI versus conventional staging procedures.
reporting domains. Nine studies had a high risk of bias in the selection of participants because they were retrospective and did not report whether patients were consecutively enrolled. Twenty-five studies were regarded as having an unclear risk of bias in confounding variables because the exact time interval between conventional staging procedures and PET scans was not reported. For the measurement of exposure domain, 6 studies had a high risk of bias because a single reader interpreted PET images and 6 studies had an unclear risk of bias because they did not report the number of readers or their experience. Regarding the blinding of outcome assessments domain, 13 studies had an unclear risk of bias as it was unclear whether PET interpretation was performed in a blinded manner and 1 study had a high risk of bias because PET interpretation was not blinded to the findings of other tests. For outcome evaluation, 10 studies showed an unclear risk of bias as the method for classifying stage was not explicitly mentioned and 2 studies had a high risk of bias as the method for confirmation of additional lesions on PET scan was reported.

Impact of $^{18}$F-FDG PET on Clinical Stage and Management

The changes in clinical stage and patient management after $^{18}$F-FDG PET in all included studies stratified by scanner type are

| Study | Events | Proportion | 95%-CI | Weight |
|-------|--------|------------|--------|--------|
| **Scanner = PET** | | | | |
| Klaeser, 2007 | 37 114 | 0.32 [0.24; 0.42] | 4.3% |
| Landheer, 2005 | 2 17 | 0.12 [0.01; 0.36] | 2.6% |
| **Random effects model** | 131 | 0.24 [0.08; 0.45] | 6.9% |
| **Scanner = PET/CT** | | | | |
| Berndorf, 2012 | 8 103 | 0.08 [0.03; 0.15] | 4.3% |
| Chandra, 2020 | 40 158 | 0.25 [0.19; 0.33] | 4.5% |
| Cochet, 2014 | 18 142 | 0.13 [0.08; 0.19] | 4.4% |
| Evangelista, 2017 (pre-op.) | 15 149 | 0.10 [0.06; 0.16] | 4.5% |
| Evangelista, 2017 (post-op.) | 18 126 | 0.14 [0.09; 0.22] | 4.4% |
| Fuster, 2008 | 16 60 | 0.27 [0.16; 0.40] | 3.9% |
| Gajjala, 2018 | 23 61 | 0.38 [0.26; 0.51] | 3.9% |
| Garami, 2012 | 18 115 | 0.16 [0.10; 0.24] | 4.3% |
| Garg, 2016 | 14 79 | 0.18 [0.10; 0.28] | 4.1% |
| Gunpal, 2012 (pre-op.) | 49 141 | 0.35 [0.27; 0.43] | 4.4% |
| Gunpal, 2012 (post-op.) | 46 195 | 0.24 [0.18; 0.30] | 4.6% |
| Jeong, 2014 | 7 178 | 0.04 [0.02; 0.08] | 4.5% |
| Koolen, 2014 | 1 62 | 0.02 [0.00; 0.09] | 3.9% |
| Kramer, 2015 | 11 101 | 0.11 [0.06; 0.19] | 4.3% |
| Manohar, 2013 | 17 43 | 0.40 [0.25; 0.56] | 3.6% |
| Ng, 2015 | 32 154 | 0.21 [0.15; 0.28] | 4.5% |
| Reddy Akepati, 2018 | 27 171 | 0.16 [0.11; 0.22] | 4.5% |
| Riegger, 2012 | 15 106 | 0.14 [0.08; 0.22] | 4.3% |
| Segert, 2010 | 7 70 | 0.10 [0.04; 0.20] | 4.0% |
| Walker, 2012 | 11 62 | 0.18 [0.09; 0.30] | 3.9% |
| Yararbas, 2018 | 69 234 | 0.29 [0.24; 0.36] | 4.6% |
| **Random effects model** | 2510 | 0.17 [0.13; 0.22] | 89.7% |
| **Scanner = PET/MRI** | | | | |
| Tanuja, 2014 | 12 36 | 0.33 [0.19; 0.51] | 3.4% |
| **Random effects model** | 36 | 0.33 [0.19; 0.50] | 3.4% |
| **Random effects model** | 2677 | 0.18 [0.14; 0.23] | 100.0% |

**FIGURE 4.** A forest plot shows the pooled proportion of changes in management compared between $^{18}$F-FDG PET, PET/CT, and PET/MRI versus conventional staging procedures.
illustrated in Figures 3 and 4, respectively. In individual studies, the proportion of alterations in staging and management ranged from 2% to 65% and from 2% to 40%, respectively.

For all the 24 studies (26 cohorts) combined, the pooled proportion of changes in stage was 25% (95% confidence interval [CI], 21%-30%). There was substantial heterogeneity based on Higgins $I^2$ statistics ($P = 0.0179$). Publication bias was not present when we used the funnel plot and Egger test (Fig. 5A; $P = 0.1079$).

Subgroup analysis according to scanner showed that there was an increasing trend in the proportion of stage changes from PET to PET/CT to PET/MRI (20% [95% CI, 2%-48%] to 25% [95% CI, 21%-30%] to 39% [95% CI, 23%-55%], respectively); however, no statistical significance was found ($P = 0.2154$). When we meta-analytically pooled studies reporting the proportion of changes stratified by initial stage, we noted different percentages of changes in staging: 11% (95% CI, 3%-22%) for stage I, 20% (95% CI, 16%-24%) for stage II, and 34% (95% CI, 27%-42%) for stage III (Supplementary Figs. 1-3, Supplemental Digital Contents 2-4, http://links.lww.com/CNM/A303, http://links.lww.com/CNM/A304, http://links.lww.com/CNM/A305; $P = 0.0002$).

Meta-analytic pooling of all 22 studies (24 cohorts) regarding changes in management indicated the pooled proportion was 18% (95% CI, 14%-23%). Higgins $I^2$ statistics demonstrated that there was substantial heterogeneity ($P = 87$). No publication bias was found (Fig. 5B; $P = 0.5934$). Subgroup analysis stratified by scanner indicated that the pooled proportions of modifications in management after PET, PET/CT, and PET/MRI were 24% (95% CI, 8%-45%), 17% (95% CI, 13%-22%), and 33% (95% CI, 19%-50%), respectively, with no statistical significance ($P = 0.0843$). Intermodality and intention-to-treat changes were available in 20 cohorts of 18 studies using PET/CT or PET/MRI (Fig. 6). The relative proportions of intermodality changes and intention-to-treat changes in terms of the summed total of each change divided by the sum of overall changes were 74% (284/386) and 70% (257/368), respectively.

### Heterogeneity Exploration

We performed subgroup analyses, which were categorized according to the type of conventional staging modality other than PET imaging in approximately one fifth of patients. When assessing the type of management changes, intermodality and intention-to-treat changes consisted of approximately 70% of the overall changes in treatment. This indicates that additional findings on PET scans may have considerable impact on therapeutic plans such as omitting neoadjuvant chemotherapy followed by surgery and starting palliative chemotherapy as well as supporting an optimal plan for the extent and site of surgical resection or RT. This can allow timely treatment minimizing unnecessary delays and avoiding adverse effects of unwarranted neoadjuvant chemotherapy, surgery, or RT. In addition, as local ablative therapy such as metastatectomy or stereotactic body RT for oligometastatic lesions can provide a local staging tools (eg, mammography, breast sonography, breast MRI) included in individual studies using PET/CT. There were no significant differences in the pooled proportions of modification in stage or management among studies that used surgical staging, those which included bone scan and sonography of the abdomen or liver, and those in which CT and/or MRI were performed, although the paucity of the included studies could limit their statistical significance (Table 4).

The results of metaregression analyses in studies using PET/CT are summarized in Table 5 and visualized in Supplementary Figure 4 (Supplemental Digital Content 5, http://links.lww.com/CNM/A306). The mean age, the proportion of advanced disease (initial stage III-IV), and the ratio of histologic grade II to III were significant factors contributing to heterogeneity. Specifically, metaregression analyses demonstrated that younger age was significantly correlated with an increased proportion of changes in staging and management after $^{18}$F-FDG PET/CT. Increase in the percentage of patients with advanced disease was related to the increased rate of stage modification after $^{18}$F-FDG PET/CT. Likewise, the proportion of grade II to III tumors was also a significant factor that increased the proportion of patient staging and management changes.

### DISCUSSION

In this study, we found that the use of $^{18}$F-FDG PET, PET/CT, or PET/MRI for initial staging of breast cancer led to changes in staging and management in 25% and 18% of patients, respectively, indicating that therapeutic approaches are altered due to PET imaging in approximately one fifth of patients. When assessing the type of management changes, intermodality and intention-to-treat changes consisted of approximately 70% of the overall changes in treatment. This indicates that additional findings on PET scans may have considerable impact on therapeutic plans such as omitting neoadjuvant chemotherapy followed by surgery and starting palliative chemotherapy as well as supporting an optimal plan for the extent and site of surgical resection or RT. This can allow timely treatment minimizing unnecessary delays and avoiding adverse effects of unwarranted neoadjuvant chemotherapy, surgery, or RT. In addition, as local ablative therapy such as metastatectomy or stereotactic body RT for oligometastatic lesions can provide a

---

**FIGURE 5.** Funnel plots of studies assessing the proportion of changes in staging (A) and management (B).
potentially curative approach.\textsuperscript{50} 18F-FDG PET may identify a subset of patients who could benefit from these locally aggressive therapies and have prolonged survival. Therefore, it seems plausible that the use of 18F-FDG PET/CT can improve the management of breast cancer patients.

Notably, there was substantial heterogeneity across the included studies for changes in both staging and management. We found that clinical stage, tumor grade, and age were significant factors that affect heterogeneity. We have reported the differential pooled proportions of stage changes according to patient's initial stage. Our result is partly consistent with current clinical guidelines in that the use of 18F-FDG PET/CT is recommended in advanced stage breast cancer,\textsuperscript{2-4} in that clinical stage changed in approximately one third of patients with stage III (34%) disease. However, our results also indicate that a nonnegligible proportion of patients in stage II (20%) and even in stage I (11%) can undergo stage changes and may benefit from the use of PET scans. These values are not significantly different from the reported proportions of stage migration from clinical stage I after 18F-FDG PET/CT in the initial staging of non–small cell lung cancer\textsuperscript{51,52} or head and neck squamous cell carcinoma,\textsuperscript{53} for which 18F-FDG PET/CT is recommended by guidelines\textsuperscript{54,55} and covered by Medicare.\textsuperscript{6} Well-designed
prospective studies (which could not be included in our meta-analysis because of overlapping study populations) reported that $^{18}$F-FDG PET/CT changed the stage in 52% (61/117) of patients with locally advanced or inflammatory breast cancer, and in 17% (22/131) of patients with stage IIA to IIA disease. Invasive tumors with higher histologic grade exhibit higher $^{18}$F-FDG uptake, which increased detectability of lesions. Grade III tumors are more frequently associated with extra-axillary nodal metastasis, for which PET scans show superior diagnostic efficacy compared with other conventional staging modalities; this may significantly influence planning fields for surgery or RT. Of note, the clinical impact of PET scans would have been greater. Fourth, there was a body of important studies that matched the scope of our review but not included in our meta-analysis. These studies reported either unsuspected nodal or distant metastasis; not being able to extract patient-based proportions. If this detailed information had been provided, the impact of PET imaging on staging and/or management. Second, there was substantial heterogeneity among the studies, and therefore, caution is required when applying our pooled results in specific clinical circumstances. Although we found that age, stage, and grade were significant factors for heterogeneity, it remains unexplained to some extent. Third, the definition of changes in staging or management may vary across studies. Several studies performed a less specific classification of stage (ie, stage III, rather than substages IIA–C) or treatment modality (ie, RT, without mention of extent and dose of radiation) that would cause an underestimation of our pooled proportions. If this detailed information had been provided, the impact of PET scans would have been greater. Fourth, there was a body of important studies that matched the scope of our review but not included in our meta-analysis. These studies reported either unsuspected nodal or distant metastasis; not being able to extract patient-based proportion would lead an underestimation of our pooled proportions of analyses. Moreover, practice patterns in breast cancer can vary widely because this cancer has a wide range of hormone receptors and molecular subtypes. Two retrospective studies by Ulaner et al and suggested that $^{18}$F-FDG PET/CT may have a greater impact on staging and treatment in triple-negative breast cancer patients compared with ER+/HER2− or HER2+ breast cancer patients.

Our study has several limitations. First, approximately half of the studies (15/29) were retrospectively conducted. If the PET scans were performed to confirm suspected lesions on conventional imaging modalities, although this was not mentioned in any of the studies, we may have overestimated the potential impact of PET imaging on staging and/or management. Second, there was substantial heterogeneity among the studies, and therefore, caution is required when applying our pooled results in specific clinical circumstances. Although we found that age, stage, and grade were significant factors for heterogeneity, it remains unexplained to some extent. Third, the definition of changes in staging or management may vary across studies. Several studies performed a less specific classification of stage (ie, stage III, rather than substages IIA–C) or treatment modality (ie, RT, without mention of extent and dose of radiation) that would cause an underestimation of our pooled proportions. If this detailed information had been provided, the impact of PET scans would have been greater. Fourth, there was a body of important studies that matched the scope of our review but not included in our meta-analysis. These studies reported either unsuspected nodal or distant metastasis; not being able to extract patient-based proportion would lead an underestimation of our pooled proportions of

### TABLE 4. Subgroup Analysis According to Conventional Staging Procedure in the Included Studies Using PET/CT

| Outcomes                  | Conventional Modalities | Studies, n | Pooled Proportion | 95% CI       | $I^2$ | $P^*$ |
|---------------------------|-------------------------|------------|-------------------|--------------|------|------|
| Change in stage           | CXR(−)/BS(−)/US(−)/CT(−)/MRI(−) | 6          | 0.22              | 0.17–0.27    | 82%  | 0.3873 |
|                           | BS(+)/US(+)/CT(+)/MRI(−) | 4          | 0.31              | 0.19–0.44    | 86%  |      |
|                           | CT(+)/MRI(−)            | 4          | 0.27              | 0.18–0.37    | 73%  |      |
|                           | CT(+)/MRI(+)            | 4          | 0.29              | 0.20–0.38    | 83%  |      |
| Change in management      | CXR(−)/BS(−)/US(−)/CT(−)/MRI(−) | 1          | 0.25              | 0.19–0.32    | NA   | 0.2638 |
|                           | BS(+)/US(+)/CT(+)/MRI(−) | 6          | 0.17              | 0.11–0.23    | 70%  |      |
|                           | CT(+)/MRI(−)            | 5          | 0.22              | 0.16–0.30    | 69%  |      |
|                           | CT(+)/MRI(+)            | 5          | 0.18              | 0.11–0.27    | 89%  |      |

*P values of test for subgroup differences.

CXR, chest x-ray; NA, not applicable; US, ultrasound.

### TABLE 5. Metaregression Analysis of the Included Studies Using PET/CT

| Outcomes | Variables | Studies, n | Slope Coefficient | 95% CI       | $P$    | $R^2*  |
|----------|-----------|------------|-------------------|--------------|-------|--------|
| Change in stage | Mean age, y | 21 | −0.0188 | −0.0362 to −0.0015 | 0.0334 | 9% |
|             | Initial stage III–IV, % | 20 | 0.0024 | 0.0009 to 0.0040 | 0.0021 | 18% |
|             | Ductal histology, % | 18 | −0.0033 | −0.0099 to 0.0032 | 0.3184 | 0% |
|             | Lobular histology, % | 18 | 0.0065 | −0.0025 to 0.0155 | 0.1596 | 0% |
|             | Grade II–III, % | 12 | 0.0101 | 0.0049 to 0.0153 | 0.0001 | 49% |
|             | HER2+ phenotype, % | 10 | 0.0007 | −0.0018 to 0.0032 | 0.5810 | 0% |
| Change in management | Mean age, y | 20 | −0.0238 | −0.0394 to −0.0081 | 0.0030 | 27% |
|             | Initial stage III–IV, % | 19 | 0.0016 | −0.0002 to 0.0033 | 0.0824 | 5% |
|             | Ductal histology, % | 15 | 0.0007 | −0.0083 to 0.0097 | 0.8816 | 0% |
|             | Lobular histology, % | 15 | −0.0044 | −0.0171 to 0.0084 | 0.5017 | 0% |
|             | Grade II–III, % | 11 | 0.0103 | 0.0054 to 0.0152 | <0.0001 | 70% |

*R represents amount of heterogeneity that can be accounted for.

CXR, chest x-ray; NA, not applicable; US, ultrasound.
changes if included in our meta-analysis. The number of currently available literature that supports the clinical importance of 18F-FDG PET scans in staging or management of newly diagnosed breast cancer patients is even greater than that of included articles. Finally, it is not yet clear whether the considerable changes in staging and management after PET scans would directly translate to improved clinical outcomes. Further studies are warranted.

CONCLUSIONS

The use of 18F-FDG PET, PET/CT, or PET/MRI substantially impacted clinical staging and management in newly diagnosed breast cancer. The pooled proportions of changes in staging and management were 25% and 18%, respectively. Intermodality and intention-to-treat changes constituted approximately 70% of the overall changes in treatment. Therefore, PET imaging may deserve routine clinical use for initial staging of breast cancer. Younger age and a higher proportion of patients with clinical stage III to IV and histologic grade II to III were significantly associated with a greater proportion of changes in stage or management after PET/CT.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
2. Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw. 2020;18:452–478.
3. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–1220.
4. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29:1634–1657.
5. Mrzo EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2014;49:211–215.
6. Centers for Medicare & Medicaid Services. Decision memo for positron emission tomography (FDG) for solid tumors (CAG-00181R). 2010.
7. Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2010;123:281–290.
8. Rong J, Wang S, Ding Q, et al. Comparison of 18 FDG PET/CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22:86–91.
9. Sun Z, Yi YL, Liu Y, et al. Comparison of whole-body PET/CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: a meta-analysis. Eur J Nucl Med Oncol. 2015;39:662–676.
10. Wen W, Xuan D, Hu Y, et al. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2019;14:e0225959.
11. Careaesia Aroztegui AP, Garcia Vicente AM, Alvarez Ruiz S, et al. 18F-FDG PET in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 2017;39:1010428317728285.
12. Bernsdorf M, Berhtelsen AK, Wielenca VT, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol. 2012;23:2277–2282.
13. Cemrik TF, Mavi A, Basu S, et al. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging. 2008;35:475–483.
14. Chandra P, Ravichander SK, Babu SM, et al. Evaluation of diagnostic accuracy and impact of preoperative positron emission tomography/computed tomography in the management of early operable breast cancer. Indian J Med. 2020;5:50–47.
15. Cochect A, Dugai-Cochet I, Riedinger JM, et al. (18F)-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:429–437.
16. Evangelista L, Cervino AR, Micheleto S, et al. Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. Nucl Med Commun. 2017;38:537–545.
17. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–4751.
18. Gajala SR, Hulikal N, Kadiyalaa S, et al. Whole-body (18F)-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) for staging locally advanced breast cancer: a prospective study from a tertiary cancer centre in South India. Indian J Med Res. 2018;147:256–262.
19. Garami Z, Hascsi Z, Varga J, et al. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol. 2012;38:51–37.
20. Garg PK, Deo SV, Kumar R, et al. Staging PET/CT scanning provides superior detection of lymph nodes and distant metastases than traditional imaging in locally advanced breast cancer. World J Surg. 2016;40:2036–2042.
21. Groheux D, Hindie E, Delod M, et al. Prognostic impact of (18F)-PET/CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–1887.
22. Gunalp B, Ince S, Karacalıoğlu AO, et al. Clinical impact of (18F)-FDG PET/CT on initial staging and therapy planning for breast cancer. Exp Ther Med. 2012;4:693–698.
23. Jeong YJ, Kang DY, Yoon HJ, et al. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes. Breast Cancer Res Treat. 2014;145:137–142.
24. Klaeser B, Wiederkehr O, Koeberle D, et al. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative stages of patients with clinically intermediate or high-risk breast cancer. Ann Oncol. 2007;18:1329–1334.
25. Koolen BB, van der Leij F, Vogel VW, et al. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer. Acta Oncol. 2014;53:50–57.
26. Krammer J, Schnitzer A, Kaisar CG, et al. (18) F-FDG PET/CT for initial staging in breast cancer patients—is there a relevant impact on treatment planning compared to conventional staging modalities? Eur Radiol. 2015;25:2460–2469.
27. Landheer ML, Stevens MG, Klinkenbijl JH, et al. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg. 2005;92:1363–1367.
28. Manohar K, Mittal BR, Bhoil A, et al. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer. Nucl Med Commun. 2013;34:557–561.
29. Ng SP, David S, Alamgeer M, et al. Impact of pretreatment combined (18F)-fluorodeoxyglucose positron emission tomography/computed tomography staging on radiation therapy treatment decisions in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2015;93:111–117.
30. Nural GSC, Nural TZ, Aytaç HO, et al. Is PET/CT necessary in the management of early breast cancer? Clin Nucl Med. 2016;41:362–365.
31. Pipperkova E, Raphael B, Altinay ME, et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med. 2007;32:429–434.
32. Reddy Akepati NK, Abubakar ZA, Bikkina P. Role of 18F-Fluorodeoxyglucose positron-emission tomography/computed tomography scan in primary staging of breast cancer compared to conventional staging. Indian J Med Res. 2018;133:190–193.
33. Riegg C, Herrmann J, Nagarajah J, et al. Whole-body PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:852–863.
34. Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET/CT in staging of clinical stage IIIB and III breast cancer. Breast. 2010;16:617–624.
35. Sen F, Akpinar AT, Ogor U, et al. The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients. Nucl Med Commun. 2013;34:571–576.
36. Taneja S, Jena A, Goel R, et al. Simultaneous whole-body (18F)-FDG PET/MRI in primary staging of breast cancer: a pilot study. Eur J Radiol. 2014;83:2231–2239.
37. Ulana GA, Castillo R, Goldman DA, et al. (18F)-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1937–1944.
38. Ulana GA, Castillo R, Wills I, et al. (18F)-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1420–1427.
39. Walker GV, Niikura N, Yang W, et al. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast.
cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012;83:1381–1386.

40. Yarbabu U, Avci NC, Yeniay L, et al. The value of ¹⁸F-FDG PET/CT imaging in breast cancer staging. Bosn J Basic Med Sci. 2018;18:72–79.

41. Groheux D, Cochet A, Humbert O, et al. ¹⁸F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):17S–26S.

42. Lin CY, Lin CL, Kao CH. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: a review and meta-analysis. Eur J Radiol. 2018;107:158–165.

43. Morièr D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

44. Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408–414.

45. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane. 2019. Available at: https://training.cochrane.org/cochrane-handbook-systematic-reviews-interventions. Accessed May 26, 2020.

46. Han S, Woo S, Kim YJ, et al. Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74:179–190.

47. Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–978.

48. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.

49. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.

50. Di Lascio S, Pagani O. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel). 2014;9:7–14.

51. Ragnanathan R, Cease K, Troeschel S, et al. Impact of staging with positron-emission tomography (PET) and comorbidities on management and survival of American veterans with stage I–III non–small cell lung cancer. Am J Clin Oncol. 2018;41:513–518.

52. Takeuchi S, Khiewvan B, Fox PS, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non–small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:906–914.

53. Nair S, Mohan S, Nilakantan A, et al. Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography scan on initial evaluation of head and neck squamous cell carcinoma: our experience at a tertiary care center in India. World J Nucl Med. 2015;14:19–24.

54. Ettinger DS, Wood DE, Aisner DL, et al. Non–small cell lung cancer, version 4.2020, NCCN clinical practice guidelines in oncology. 2020.

55. Pfister DG, Spencer S, Adelstein D, et al. Head and Neck Cancers, version 1.2020, NCCN clinical practice guidelines in oncology. 2020.

56. Groheux D, Giachetti S, Delord M, et al. ¹⁸F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013;54:5–11.

57. Groheux D, Giachetti S, Espié M, et al. The yield of ¹⁸F-FDG PET/CT in patients with clinical stage IIIA, IIIB, or IIIA breast cancer: a prospective study. J Nucl Med. 2011;52:1526–1534.

58. Sanli Y, Kuyumcuoz, Ozkan ZG, et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 2012;26:345–350.

59. Gil-Rendo A, Martinez-Regueira I, Zornoza G, et al. Association between ¹⁸F fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166–170.

60. Riedl CC, Slobod E, Jobelshon M, et al. Retrospective analysis of ¹⁸F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55:1578–1583.

61. Alberini JL, Lerebours F, Wartski M, et al. ¹⁸F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115:5038–5047.

62. Aliyev A, Yilmaz Aksoy S, Özhan M, et al. The role of FDG PET/CT in detection of distant metastasis in the initial staging of breast cancer. Turk J Med Sci. 2016;46:349–360.

63. Bitencourt AGV, Andrade WP, da Cunha RR, et al. Detection of distant metastases in patients with locally advanced breast cancer: role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans. Radiol Bras. 2017;50:211–215.

64. Choi Y, Shin YD, Kang YH, et al. The effects of preoperative (18)F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study. J Breast Cancer. 2012;15:441–448.

65. Fosse P, Girault S, Capitan O, et al. FDG-PET in the initial staging of locally advanced breast cancer before neoadjuvant chemotherapy. Médecine Nucléaire. 2012;36:69–76.

66. Hancerliogullari O, Arslan N, Görgülü S, et al. 2-[¹⁸F]-fluoro-2-deoxy-D-glucose positron emission tomography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. Turk J Med Sci. 2012;42:1214–1221.

67. Hogan MP, Goldman DA, Dashovsky B, et al. Comparison of ¹⁸F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med. 2015;56:1674–1680.

68. Koolen BB, Vanrnek Peeters MJ, Aukema TS, et al. ¹⁸F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012;131:117–126.

69. Koolen BB, Valdés Olmos RA, Elkuizen PH, et al. Locoregional lymph node involvement on ¹⁸F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat. 2012;135:231–240.

70. Lebon V, Alberini JL, Pierga JY, et al. Rate of distant metastases on ¹⁸F-FDG PET/CT at initial staging of breast cancer: comparison of women younger and older than 40 years. J Nucl Med. 2015;56:257.

71. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249–1254.

72. Niikura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16:1111–1119.

73. van der Hoeven JJ, Krah NC, Heekstra OS, et al. ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol. 2004;22:1253–1259.